Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Skip More from NICE submenu
Explore more from NICE
What NICE does
About us
Reusing our content
Implementing NICE guidance
News, blogs and podcasts
Contact us
Get involved
Careers
Join a committee
Comment on a consultation
Close menu
My account
Consultation responses
Sign in
You are here:
Home
NICE Guidance
NICE Advice
Evidence summaries
COVID-19 rapid evidence summary: Tocilizumab for COVID-19
Evidence summary
Reference number:
ES33
Published:
15 January 2021
Last updated:
24 February 2021
This guideline has been updated and replaced by
NICE COVID-19 rapid guideline NG191
.
Back to top